Search
Editas Medicine Inc
EDITAdd to Watchlist
2.705USD
-0.025-0.92%
Market hours 10/07, 10:07（ET）
453.87MMarket Cap
LossP/E TTM
Editas Medicine Inc (EDIT) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Editas Medicine Inc in the past month.
Buy
2 Strong Buy
6 Buy
3 Hold
2 Sell
0 Strong Sell
Target Price
6.000USD+129.01%
EDIT Analyst Recommendation Trends
In the current month, EDIT has received 6 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. EDIT average Analyst price target in the last month is 6.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
2
2
2
2
2
2
2
6
6
6
6
5
5
5
5
3
3
4
4
5
5
6
6
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
13
13
14
14
14
14
15
15
EDIT Analyst Rating for Peer Comparison
Updated: Oct 6, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, EDIT EPS is projected to reach -0.189 in FY2026Q3, following reported EPS of -0.153 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.26
-0.26
-0.27
-0.19
-0.18
Actual
-0.06
-0.26
-0.15
--
--
Surprise
+77.64%
+3.21%
+43.38%
--
--
FAQs
What is Editas Medicine Inc's expected revenue for the next quarter?
Editas Medicine Inc's expected revenue is 4.53M.
What is Editas Medicine Inc's price target?
Analysts forecast that Editas Medicine Inc's price target is USD 6.00, with the highest forecast at USD 15.00 and the lowest forecast at USD 1.00.
How have Editas Medicine IncEDIT's recent earnings per share performed?
The market expectation was USD -0.15, while Editas Medicine IncEDIT's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for Editas Medicine Inc?
Based on the ratings of Editas Medicine Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.